Zobrazeno 1 - 10
of 188
pro vyhledávání: '"R Roylance"'
Autor:
E.R. Copson, J.E. Abraham, J.P. Braybrooke, D. Cameron, S.A. McIntosh, C.O. Michie, A.F.C. Okines, C. Palmieri, F. Raja, R. Roylance, S. Spensley
Publikováno v:
Breast, Vol 72, Iss , Pp 103582- (2023)
Background: There is currently no standardised definition for patients at high risk of recurrence of human epidermal growth factor receptor 2 (HER2)-negative early breast cancer (eBC; stages 1–3) after surgery. This modified Delphi panel aimed to e
Externí odkaz:
https://doaj.org/article/a65c03fcfda54d3bb961d83f7100eb9a
Autor:
A, Lerner, K, Keshwani, A, Okines, B, Sanderson, R E, Board, M, Flynn, E, Sharkey, A, Konstantis, R, Roylance, D, Hanna, J, King, R, Murphy, F, Rehman, A E, Guppy, C, Westbury, E, Takeuchi, E, Spurrell, H K, Jayaweera, F, Raja
Publikováno v:
Clinical Oncology. 34:261-266
Fulvestrant is a selective oestrogen receptor (ER) degrader used in postmenopausal women with hormone receptor-positive advanced breast cancer. The study aim was to analyse demographics and outcomes of UK patients treated with fulvestrant monotherapy
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Keun-Wook Lee, Natasha Lukashchuk, Andrew Goldwin, Bienvenu Loembe, Graeme Parr, Irene Kang, Tobias Arkenau, R Roylance, Mario Campone, Claire Smith, Wassim Abida, Andrew J. Pierce, Duncan I. Jodrell, Alan Lau, Elhan Sanay, Sophie Postel-Vinay, Juanita Lopez, Sunyoung Rha, Emma Dean, Matthew G Krebs, Seock-Ah Im
Publikováno v:
Cancer Research. 81:PS11-18
Background: Alterations in BRCA1/2 are associated with ~9% of all BCs. Ola (a poly ADP-ribose polymerase inhibitor [PARPi]) is approved for treating pts with HER2-negative metastatic BC with germline BRCA mutation (gBRCAm), demonstrating an improveme
Autor:
Maia Gogiladze, Amy McCullough, Andrew M Wardley, Chao Li, Boris Krastev, Andrew P. Beelen, Marina Maglakelidze, Rajesh K. Malik, Iurie Bulat, Yili Pritchett, Richard D. Baird, C. Murias, Jessica A. Sorrentino, Adrian Crijanovschi, R Roylance
Publikováno v:
Cancer Research. 80:P1-19
Approved CDK4/6 inhibitors have demonstrated significant improvements in progression free survival when combined with fulvestrant in patients with HR+/HER2- advanced breast cancer, though limited by neutropenia and gastrointestinal side effects. Lero
Autor:
Luke Hughes-Davies, Ellen Copson, Bryony Harrop, Karen Pinilla Alba, Paula del Rosario, Anne C Armstrong, Nikolaos Demiris, R Roylance, Emma McMurtry, L Grybowicz, Wendi Qian, Caron Harvey, Marc Tischkowitz, Karen McAdam, Elena Provenzano, Anne-Laure Vallier, Helena M. Earl, Stanly Thomas, Jean Abraham
Publikováno v:
Cancer Research. 80:P3-10
Background: Triple negative breast cancers (TNBCs) are an aggressive and diverse subgroup with no specific targeted therapies currently available. Basal TNBCs show some phenotypic and molecular similarities with germline BRCA mutated BC (gBRCA). In g
Autor:
Fharat Raja, R Roylance, Arjun K. Ghosh, Emma Spurrell, Sara Tyebally, Michael Malloupas, Daniel H Chen
Publikováno v:
Current Cardiology Reports. 23
Cardiotoxicity can occur acutely during breast cancer treatment and impact the potential for the intended cancer treatment regime to be completed, or as a late effect affecting cancer survivorship. Indeed, the most common cause of mortality in female
Autor:
Anjui Wu, Gehan Soosaipillai, Christopher C T Sng, R Roylance, Sarah Benafif, Heather Shaw, Yien Ning Sophia Wong, Alvin J.X. Lee, Neha Chopra, D. Ottaviani, Myria Galazi
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Frontiers in Oncology
Frontiers in Oncology
BackgroundThe COVID-19 pandemic remains a pressing concern to patients with cancer as countries enter the second peak of the pandemic and beyond. It remains unclear whether cancer and its treatment contribute an independent risk for mortality in COVI
Autor:
R Roylance, Iain R. Macpherson, James P Morden, Richard D. Baird, A Ring, Nicholas C. Turner, Hannah Bye, Laura Moretti, P Proszek, Charlotte Fribbens, Judith M Bliss, Andrew M Wardley, Sarah Kernaghan, Claire Snowdon
Publikováno v:
Cancer Research. 78:OT1-06
Introduction Circulating tumour DNA (ctDNA) is found in the plasma of over 90% of patients with advanced breast cancer (BC). Screening for the presence of mutations in ctDNA provides a current assessment of the genetic profile of the patient's recurr